Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.

Bayer AG NA

Mr. William N. Anderson

Chairman of the Management Board & CEO

Mr. Wolfgang U. Nickl

CFO & Member of Management Board

Mr. Stefan  Oelrich

Head of the Pharmaceuticals Division & Member of the Board of Management

Mr. Rodrigo  Santos

Member of Management Board & President of the Crop Science Division

Ms. Heike  Prinz

Chief Talent Officer, Labor Director & Member of Management Board

Mr. Julio  Triana

Member of Management Board & President of Consumer Health Division

Dr. Sebastian  Guth Ph.D.

Chief Operating Officer

Amanda  McClerren

Chief Information Officer, Head-Digital Transformation & IT-Crop Science Division

Dr. Jost  Reinhard

Head of Investor Relations

Dr. Thomas  Laubert

Head of Law, Patents & Compliance

BAYN's next earnings is on March 5, 2025 (Before Market Open)

BAYN's latest dividend is 0.11 EUR on April 29, 2024

Bayer AG NA (BAYN) Stock Analysis, Discussion Forum and Financial Metrics - XETRA Exchange

Bayer AG NA (BAYN) Earnings Report Date and History | XETRA

BAYN's next earnings is on March 5, 2025 (Before Market Open)

When is the earnings report for BAYN?

BAYN Earnings History

BAYN's latest dividend is 0.11 EUR on April 29, 2024

BAYN Stock Discussion Forum and Message Board

News for XETRA: BAYN